Market open· · BRL · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Randoncorp’s fair value estimate has been trimmed from R$9.38 to R$9.03, a small R$0.35 adjustment that reflects refreshed assumptions rather than a fundamental rethink of the story. The shift lines up with how analysts often fine tune targets when they want their models to better match updated revenue growth expectations while still keeping the core thesis intact. As you read on, keep an eye on how these kinds of modest revisions shape the ongoing narrative around Randoncorp and how you can...
Randoncorp’s price target has seen a notable revision, reflecting a surge of optimism in the market. This update comes as new clinical developments and regulatory progress spark increased confidence among analysts and investors alike. Stay tuned to discover how you can keep ahead of shifts in Randoncorp’s narrative as expectations continue to evolve. Stay updated as the Fair Value for Randoncorp shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.